Imatinib Krka D.D. (Imatinib)

Imatinib binds to the ATP‑binding site of BCR‑ABL, KIT and PDGFR tyrosine kinases, blocking their enzymatic activity. This inhibition stops downstream phosphorylation events that normally promote cell proliferation and survival, thereby reducing the growth of cancer cells that depend on these pathways.

The exact dose and dosing schedule are determined by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. Patients should follow the individualized regimen provided by their healthcare professional.

Safety data for imatinib in pregnancy and lactation are limited. It is generally advised that women of child‑bearing potential discuss potential risks with their physician, and that breastfeeding be avoided unless the benefits outweigh the possible risks to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first BCR‑ABL tyrosine‑kinase inhibitor approved for CML and remains a standard first‑line option. Newer agents such as dasatinib and nilotinib have different potency and side‑effect profiles, but imatinib’s long‑term safety record and extensive clinical experience make it a widely used reference therapy.

Store the product at temperatures below 25 °C in its original packaging. Protect it from moisture, excessive heat and direct sunlight to maintain stability and potency throughout its shelf life.

Imatinib Krka D.D. is taken orally, usually as a whole tablet swallowed with water. It can be taken with or without food, but patients should follow any specific instructions from their prescriber regarding timing relative to meals.

Serious risks include severe neutropenia, hepatotoxicity, cardiac failure, pulmonary hypertension, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for these events and report any concerning symptoms promptly.

Patients with known hypersensitivity to imatinib or any of its excipients should avoid the drug. Caution is also advised for individuals with pre‑existing severe liver disease, uncontrolled cardiac conditions, or those taking medications that strongly interact with imatinib metabolism.